The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...

“After treatment with enzalutamide, PSA levels decline due to potent androgen receptor blockade and cell death,” Armstrong ...

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment ...

For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

ARPI-based doublet regimens improve progression-free survival broadly, yet agent choice and magnitude of benefit can vary with age and comorbidity profiles, including heightened cardiovascular and ...

Transdermal oestradiol patches are non-inferior to luteinising hormone-releasing hormone agonists for metastasis free survival in locally advanced prostate cancer, a study shows.

A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as ...

A pilot trial of trans-arterial docetaxel chemoperfusion plus darolutamide and ADT for mHSPC led to rapid and profound PSA suppression with manageable safety. In a phase 2 trial of patients with ...

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer Alliance A222001: Oxybutynin Versus Placebo for ...

A recent study published in The New England Journal of Medicine found that transdermal estradiol (tE2) therapy was ...